Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ, United Kingdom
IOPIDINE 5mg/ml Eye Drops, Solution.
| Pharmaceutical Form |
|---|
|
Eye drops, solution. A colourless to pale yellow solution. |
1 ml of solution contains Apraclonidine 5 mg (as hydrochloride).
Excipients with known effect: 1 ml of solution contains 0.1 mg benzalkonium chloride.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Apraclonidine |
Apraclonidine is an α2-adrenergic receptor agonist and a weak α1-adrenergic receptor agonist. It is used for the prevention and treatment of postsurgical intraocular pressure elevation. |
| List of Excipients |
|---|
|
Benzalkonium chloride |
5 ml and/or 10 ml white LDPE DROP-TAINER dispensers with a natural LDPE dispensing plug and white polypropylene closure.
Not all pack sizes may be marketed.
Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ, United Kingdom
PL 00101/0996
29 December 1994 / 02 December 2009
| Drug | Countries | |
|---|---|---|
| IOPIDINE | Austria, Australia, Canada, Finland, France, Ireland, Israel, Malta, Netherlands, New Zealand, Tunisia, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
